New clinical guidelines have been announced for the treatment of men with metastatic castration-resistant prostate cancer (CRPC) by the American Society of Clinical Oncology (ASCO) and Cancer Care Ontario (CCO). Ethan Basch, MD, director of the Cancer Outcomes Research Program at UNC Lineberger Comprehensive Cancer Center, served as the co-chair of the ASCO/CCO expert panel that developed the guideline.
Upstream of the proteins that cancer cells use to proliferate sits RBM4, a gene-splicing protein that UNC researcher Zefeng Wang, PhD, discovered is drastically reduced in human lung and breast cancer cells.
Research led by UNC’s Kathleen Caron, PhD, shows that halting the protein CXCR7 leads to over activation of adrenomedullin, a hormone needed at proper levels for normal cardiovascular development
Thanks to you, 2013-14 was a big year for UNC Lineberger.
UNC Lineberger secures three major NCI grants to advance the nation’s clinical trials program.
Carey Anders, MD, UNC Lineberger member and associate professor, was a presenter and moderator at The 13th Annual Round Asia Oncology Forum (RAOF) in Hong Kong on August 29 - 30, 2014. The theme of this year’s forum was “Expanding our armory in personalized cancer treatment.”
The UNC Eshelman School of Pharmacy has received a $3 million gift from philanthropist and pharmaceutical-industry executive Fred Eshelman. Eshelman’s gift will support the work of the School’s Center for Integrative Chemical Biology and Drug Discovery, led by UNC Lineberger member Stephen Frye, PhD. The center is dedicated to evaluating and developing potential drug targets discovered by UNC faculty.
James Swenberg, PhD, DVM, DACVP, Environmental Science & Engineering, Cancer Genetics, and additional co-authors have published "The endogenous exposome" in the July 2014 issue of DNA Repair. In the review, authors focused on the endogenous exposome, the DNA damage that arises from the production of endogenous electrophilic molecules in cells.
The National Cancer Institute has awarded Ben Major, PhD, assistant professor of Cell Biology and Physiology, University of North Carolina at Chapel Hill and UNC Lineberger Comprehensive Cancer Center, with an R21 award of $275,000 to support his project “Mass spectrometry-coupled hypermorphic functional genomics”. The goal of the research is to develop gain-of-function screening technology to connect gene overexpression with signal transduction in cancer.
Six researchers have been awarded 2014 University Cancer Research Fund (UCRF) Innovation Awards for promoting innovative and new ideas in cancer research at the University of North Carolina at Chapel Hill.
UNC Health Care and Rex Healthcare co-sponsored “Field of Hope” at the Durham Bulls game on Saturday, August 23 with a portion of special ticket sales going to the Kay Yow Cancer Fund.
The Lung Cancer Initiative of NC hosted a statewide Lung Cancer Summit on August 23 at the N.C. Cancer Hospital. Lung cancer advocates were bolstered with training, resources, knowledge and the courage to take action. UNC Lineberger Comprehensive Cancer Center was the Host Sponsor of the event.
For more than 20 years, Sharon Campbell, PhD, has been studying Ras, a protein implicated in 30 percent of all cancers. Now she’s on the hunt for alternative ways to shut the protein down.
Kirsten Bryant, PhD, was recently recognized by the Pancreatic Cancer Action Network for her dual role in the fight against pancreatic cancer.
UNC Lineberger Comprehensive Cancer Center researchers have developed a new integrated approach to pinpoint the genetic “drivers” of cancer, uncovering eight genes that could be viable for targeted breast cancer therapy. The study, published online August 24 in Nature Genetics, was authored by Michael Gatza, PhD, lead author and post-doctoral research associate; Grace Silva, graduate student; Joel Parker, PhD, director of bioinformatics, UNC Lineberger; Cheng Fan, research associate; and senior author Chuck Perou, PhD, professor of genetics and pathology.
Part of More Than $24.7 Million Awarded in New Grants by the St. Baldrick’s Foundation
An international scientific collaboration led by researchers at UNC has revealed new insights into the unique genetic alterations that contribute to a rare form of kidney cancer.
Angiogenesis inhibitors are a class of drugs commonly used in cancer therapy. However, there isn’t a way to identify patients who will benefit the most from treatment with these drugs. A new $275,000 grant could help Federico Innocenti, MD, PhD, and his team identify such patients based on their genetic profile.
Margaret L. Gulley, MD, served as a coauthor on The Cancer Genome Atlas publication of “The Comprehensive Molecular Characterization of Gastric Adenocarcinoma” in the journal Nature. The paper identifies four subtypes of the cancer, which could provides information to allow for better patient tumor type identification and the development of targeted therapies for the cancer.
Stephanie Wheeler, PhD, and Michael Pignone, MD, MPH, published “Regional variation in colorectal cancer testing and geographic availability of care in a publicly insured population” in the journal Health and Place. The paper found that less than 50 percent of eligible individuals had evidence of colorectal (CRC) testing.